Patents Assigned to Bloodworks
  • Patent number: 12030956
    Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: July 9, 2024
    Assignee: Bloodworks NW
    Inventor: James Charles Zimring
  • Patent number: 11892458
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more compounds in a red blood cell sample are provided.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: February 6, 2024
    Assignee: Bloodworks NW
    Inventor: James Charles Zimring
  • Patent number: 11693018
    Abstract: Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing or not releasing the RBC unit for transfusion based on the results.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: July 4, 2023
    Assignee: Bloodworks NW
    Inventor: James Charles Zimring
  • Patent number: 11397183
    Abstract: The instant disclosure provides biomarkers and methods for identifying subjects at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. For example, adverse event biomarkers may be measured in a subject before pre-conditioning chemotherapy, before immunotherapy (e.g., adoptive immunotherapy infusion comprising a chimeric antigen receptor (CAR) modified T cell), or shortly after pre-conditioning chemotherapy and/or immunotherapy. Exemplary biomarkers include temperature, cytokine levels and endothelial activation biomarkers, such as angiopoietin 2, von Willebrand factor (vWF), ratio of angiopoietin 2 to angiopoietin 1, and ratio of ADAMTS13 to vWF. Also provided are methods of treating subjects identified as at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both to minimize such potential adverse events.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: July 26, 2022
    Assignees: Fred Hutchinson Cancer Center, University of Washington, Bloodworks Northwest
    Inventors: W. Conrad Liles, Cameron J. Turtle, David G. Maloney, Stanley R. Riddell, Mark M. Wurfel, Jose Lopez, Dominic Chung, Junmei Chen
  • Publication number: 20220204645
    Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.
    Type: Application
    Filed: January 7, 2022
    Publication date: June 30, 2022
    Applicant: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 11248060
    Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 15, 2022
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 11181534
    Abstract: Compositions and methods useful for point of care testing for hemophilia by measuring coagulation factor levels are provided.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: November 23, 2021
    Assignee: Bloodworks
    Inventors: Jill Marie Johnsen, Barbara A. Konkle
  • Publication number: 20210356479
    Abstract: Compositions and methods which are useful for determining the sensitivity and specificity of antibody detection reagents are disclosed.
    Type: Application
    Filed: June 25, 2021
    Publication date: November 18, 2021
    Applicant: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 11105820
    Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: August 31, 2021
    Assignees: University of Washington through its Center for Commercialization, Bloodworks
    Inventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
  • Patent number: 11085937
    Abstract: Compositions and methods which are useful for determining the sensitivity and specificity of antibody detection reagents are disclosed.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: August 10, 2021
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 11047868
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 29, 2021
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Publication number: 20210088535
    Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.
    Type: Application
    Filed: September 28, 2020
    Publication date: March 25, 2021
    Applicants: University of Washington through its Center for Commercialization, Bloodworks
    Inventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
  • Publication number: 20200408785
    Abstract: Photonic devices, systems, and methods for detecting an analyte in a biological solution (e.g., whole blood) are provided. Representative photonic devices are optical ring resonators having nanoscale features and micron-sized diameters. Due to the compact size of these devices, many resonators can be disposed on a single substrate and tested simultaneously as a sample is passed over the devices. Typical analytes include blood cells, antibodies, and pathogens, as well as compounds indicative of the presence of blood cells or pathogens (e.g., serology). In certain embodiments, blood type can be determined through photonic sensing using a combination of direct detection of blood cells and serology. By combining the detection signals of multiple devices, the type of blood can be determined.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicants: University of Washington through its Center for Commercialization, Bloodworks
    Inventors: Daniel M. Ratner, Jill M. Johnsen, James T. Kirk, José A. López, Norman D. Brault, Shaoyi Jiang
  • Patent number: 10830777
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more compounds in a red blood cell sample are provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: November 10, 2020
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 10816557
    Abstract: Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing the RBC unit for transfusion based on the results.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: October 27, 2020
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 10785967
    Abstract: Provided is a transgenic mouse with modified glucose-6-phosphate dehydrogenase which can be used as a model and screening tool for various aspects of glucose-6-phosphate dehydrogenase deficiency.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: September 29, 2020
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 10786653
    Abstract: A catheter assembly with segmented or step-wise deployment stabilization system includes a base or handle, puncture needle extending from the handle, and a deployment mechanism or mechanisms to selectively extend from the distal end of the needle for first length a hollow stabilizing component and as a second step to a second further length a stabilizing guide wire element. The needle will gain sub-dermal access to the patient to the intended position for deployment of a catheter. Hollow stabilizing component provides for a first additional guide and support for a catheter sheath from the distal end of the needle. The stabilizing wire element provides additional length, guide and support for the catheter sheath. The hollow stabilizing component has some degree of flexibility as does the guide wire to minimize chance of damage to surrounding tissue.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: September 29, 2020
    Assignee: Bloodworks LLC
    Inventors: Joshua J. Galgano, Hanjun Kim, Jr., Robert J. Anderson
  • Patent number: 10705093
    Abstract: Compositions and methods for determining the level of thiol and disulfide containing molecules in a sample are provided. The compositions and methods can be used to determine the level of oxidative stress in a subject with or without antioxidant treatment. Also provided are biomarkers of oxidative stress.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: July 7, 2020
    Assignee: Bloodworks
    Inventors: Xiaoyun Fu, Shelby A. Cate, Jose Aron Lopez, Junmei Chen, Barbara A. Konkle
  • Patent number: 10677781
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 9, 2020
    Assignee: Bloodworks
    Inventors: James Charles Zimring, Karen S. de Wolski
  • Publication number: 20200158740
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
    Type: Application
    Filed: January 23, 2020
    Publication date: May 21, 2020
    Applicant: Bloodworks
    Inventor: James Charles Zimring